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Background: Interleukin-12 receptor β (IL-12Rβ2) knock-out mice 
develop lung adenocarcinoma, and epigenetic silencing by CpG meth-
ylation leads to loss of this gene in B-cell malignancies. The aim of this 
study was to determine whether IL-12Rβ2 methylation is a common 
feature in human lung cancer.
Methods: We examined mRNA expression of IL-12Rβ2 in lung cancer 
cell lines, and normal bronchial, and tracheal epithelial cells using RT-
PCR, and we examined the methylation status of IL-12Rβ2 in primary 
lung cancers.
Results: Loss of expression was found in 10 of 13 (77%) NSCLC cell 
lines, and 2 of 5 (40%) SCLC cell lines compared with normal bron-
chial or tracheal cells. Treatment of 11 expression-negative cell lines 
with a demethylating agent restored expression in all cases. Aberrant 
methylation status of IL-12Rβ2 gene was reversely concordant with its 
mRNA expression. IL-12Rβ2 methylation was detected in 96 of 230 
NSCLCs (42%) and 3 of 6 SCLCs (50%). IL-12Rβ2 rmethylation cor-
related with poorer prognosis in lung adenocarcinomas (hazard ratio = 
2.33, p = 0.0059).
Conclusions: We conclude that epigenetic silencing of IL-12Rβ2 is a 
frequent event in lung cancers. Aberrant methylation of this gene seems 
to be a useful predictor of long-term outcome for adenocarcinoma of 
the lung.
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Background: Activation of the epidermal growth factor receptor 
(EGFR) in cancer cells has been shown to promote processes involved 
in tumor cell proliferation, angiogenesis, invasion, and metastasis, and 
to inhibit apoptosis. The purpose of the present study is to verify the 
role of genetic alterations involved in the EGFR pathways in non-small 
cell lung cancer (NSCLC) development.
Methods: We analyzed mutations of the EGFR, KRAS and PIK3CA 
genes and ampliﬁcation of the loci corresponding to those genes in 
primary tumors from 96 patients with NSCLC. Mutation analyses of 
EGFR (exon 19 and 21), KRAS (exon 2 and 3), and PIK3A (exon 9 
and 20) were performed by the PCR-direct sequencing method. Gene 
ampliﬁcation analyses were performed by the ﬂuorescent in situ hy-
bridization method.
Results: EGFR, KRAS, and PIK3CA gene mutations were found in 
22 (23%), 2 (2%), and 3 (3%) of 96 NSCLCs, respectively. The copy 
number gains of these genes were 26 (27%), 10 (10%), and 19 (20%) 
of them, respectively. On the whole, 55 (57%) of the 96 NSCLCs had 
one or the other gene alterations. The gene alterations were evenly 
found in cases with early stage disease as well as in those with ad-
vanced disease. It is suggested that these gene alterations play essential 
roles in the initial step of lung carcinogenesis. EGFR gene mutations 
were preferentially detected in females (34.1%, 14/41), non-smokers 
(50.0%, 14/28), and adenocarcinomas (35.1%, 20/57), with statistical 
signiﬁcances (Chi-square test, P < 0.05), which conﬁrmed previous 
observations. In contrast, PIK3CA gene ampliﬁcation were preferen-
tially detected in males (29.1%, 16/55), smokers (34.1%, 16/51), and 
squamous cell carcinomas (41.3%, 12/29) (Chi-square test, P < 0.05). It 
is suggested that certain carcinogens in the tobacco smoke might have 
caused PIK3CA gene ampliﬁcation to promote squamous cell carci-
noma development. 
Conclusions: The pathway mediated through EGFR, KRAS and 
PIKCA gene has critical role in the development of NSCLC. NSCLCs 
can be divided into speciﬁc molecular subsets according to the genetic 
alterations in this pathway.
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Cancer is worldwide problem and lung cancer is one of the frequent 
ones causing ca 1 million deaths every year. Although early stage lung 
cancer is in most cases surgically curable, about 80% of lung cancer 
cases due to tumour spread or distant metastases need either radio-
therapy, adjuvant or neoadjuvant polychemotherapy. Despite of certain 
success achieved in the ﬁeld of combined therapy, the prolonged use of 
it is limited by developing resistance to drugs and side effects of this 
treatment.
In everyday lung cancer diagnostics histological classiﬁcation is used. 
Accordingly, lung cancer is divided to small cell lung carcinoma (20% 
of all lung cancers) and non-small cell lung carcinoma (NSCLC, 80% 
of all lung cancers) including three main groups: squamous cell carci-
noma (20-35%), giant cell carcinoma (4.5-15%) and adenocarcinoma 
(30-50%). Despite of lung cancer histological subgroup diagnostics, 
the clinical course of the same stage patients is quite different. This fact 
suggests that histological form of cancer is not sufﬁcient predictor of 
clinical course of the disease.
The cancer (120) and control samples of the current study originate 
from Tartu University Hospital and are collected from 28.11.2002 to 
31.12.2006. Tissue samples were snap frozen in liquid nitrogen during 
the operation and processed in RNAlater ICE (Ambion) to elimi-
nate RNA any degradation. RNA was extracted using RiboPure Kit 
(Ambion) which was followed by RNA quantization (Nanodrop) and 
quality control on Agilent Bioanalyzer Lab-on-a-Chip technology. RIN 
value cut-off was set to 7. 
In the current study we have used Illumina whole genome gene expres-
sion arrays of 47 000 features to monitor molecular patterns of different 
NSCLC samples in hope to ﬁnd differentially expressed genes that 
